KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 29.46%.

  • Alnylam Pharmaceuticals' EBIT Margin rose 448100.0% to 29.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.0%, marking a year-over-year increase of 189900.0%. This contributed to the annual value of 7.87% for FY2024, which is 75700.0% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' EBIT Margin stood at 29.46%, which was up 448100.0% from 2.09% recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' EBIT Margin registered a high of 60.26% during Q1 2025, and its lowest value of 104.89% during Q1 2021.
  • Its 5-year average for EBIT Margin is 37.64%, with a median of 46.92% in 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' EBIT Margin skyrocketed by 1261200bps in 2023 and then crashed by -438500bps in 2024.
  • Alnylam Pharmaceuticals' EBIT Margin (Quarter) stood at 75.26% in 2021, then rose by 25bps to 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then surged by 33bps to 17.73% in 2024, then skyrocketed by 266bps to 29.46% in 2025.
  • Its EBIT Margin stands at 29.46% for Q3 2025, versus 2.09% for Q2 2025 and 60.26% for Q1 2025.